Why the study?
Nonobstructive HCM causes notable morbidity, yet no approved pharmaceutical therapies target its underlying pathophysiology.
This narrative review provides a comprehensive overview of nonobstructive hypertrophic cardiomyopathy, emphasizing the heterogeneity of the disease, diagnostic considerations, and the urgent need for targeted therapies.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to morbidity in nonobstructive HCM without approved options; leaves open targeted therapy trials.
Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable degree of morbidity, including daily life limitations, ventricular tachyarrhythmias, progression to heart failure, and atrial fibrillation. No approved pharmaceutical therapies target the pathophysiology of nonobstructive HCM, although several clinical trials are underway. This narrative review provides a comprehensive overview of nonobstructive HCM, focusing on epidemiology, natural history, genetics, pathophysiology, clinical manifestations, diagnosis, burden of disease, and current treatments and ongoing clinical trials.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: